COV Stock Overview
A medical diagnostics and devices company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Cleo Diagnostics Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.36 |
| 52 Week High | AU$0.48 |
| 52 Week Low | AU$0.16 |
| Beta | 0 |
| 1 Month Change | 8.96% |
| 3 Month Change | 1.39% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 128.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| COV | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | 1.4% | 1.1% | 0.5% |
| 1Y | n/a | 1.3% | 7.4% |
Return vs Industry: Insufficient data to determine how COV performed against the Australian Medical Equipment industry.
Return vs Market: Insufficient data to determine how COV performed against the Australian Market.
Price Volatility
| COV volatility | |
|---|---|
| COV Average Weekly Movement | 7.2% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in AU Market | 16.9% |
| 10% least volatile stocks in AU Market | 3.0% |
Stable Share Price: COV has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: COV's weekly volatility has decreased from 14% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | n/a | Richard Allman | www.cleodx.com |
Cleo Diagnostics Ltd, a medical diagnostics and devices company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia. The company provides CleoDX pre-surgical triage tests which measures a combination of biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing intellectual property and patents.
Cleo Diagnostics Ltd Fundamentals Summary
| COV fundamental statistics | |
|---|---|
| Market cap | AU$46.90m |
| Earnings (TTM) | -AU$3.76m |
| Revenue (TTM) | AU$210.81k |
222.5x
P/S Ratio-12.5x
P/E RatioIs COV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COV income statement (TTM) | |
|---|---|
| Revenue | AU$210.81k |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$210.81k |
| Other Expenses | AU$3.97m |
| Earnings | -AU$3.76m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.029 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,783.22% |
| Debt/Equity Ratio | 0% |
How did COV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 12:54 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cleo Diagnostics Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|